Table 5 of Mykkänen, Mol Vis 2012; 18:2338-2351.
Limit1 | Term | Count | Fold enrichment | p-value2 |
---|---|---|---|---|
HFD versus NCD | ||||
upregulated (n=431, 2 unknown) | ||||
Dilated cardiomyopathy | 7 | 3.5 | 0.01 | |
Hypertrophic cardiomyopathy (HCM) | 6 | 3.3 | 0.03 | |
MAPK signaling pathway | 11 | 1.9 | 0.06 | |
down regulated (n=374, 3 unkwown) | ||||
Apoptosis | 11 | 6.2 | 0 | |
Calcium signaling pathway | 10 | 2.6 | 0.02 | |
Melanogenesis | 6 | 2.9 | 0.05 | |
Long-term potentiation | 5 | 3.5 | 0.05 | |
HFD+BB versus NCD | ||||
upregulated (n=395, 2 unknown) | ||||
Systemic lupus erythematosus | 7 | 3.5 | 0.01 | |
Colorectal cancer | 6 | 3.6 | 0.02 | |
down regulated (n=410, 3 unknown) | ||||
Apoptosis | 10 | 5 | 0 | |
Calcium signaling pathway | 10 | 2.3 | 0.03 | |
Gap junction | 6 | 3.2 | 0.05 | |
HFD+BB versus HFD: | ||||
upregulated (n=393, 1 unknown) | ||||
Systemic lupus erythematosus | 7 | 3.4 | 0.02 | |
down regulated (n=412, 4 unknown) | ||||
Apoptosis | 9 | 4.7 | 0 | |
NCD+BB versus NCD: | ||||
upregulated (n=416, 2 unknown) | ||||
Systemic lupus erythematosus | 8 | 3.6 | 0.01 | |
down regulated (n=389, 3 unknown) | ||||
Apoptosis | 9 | 5.1 | 0 | |
MAPK signaling pathwway | 11 | 2 | 0.04 | |
Calcium signaling pathway | 9 | 2.3 | 0.04 |